Second-Line Treatment Options in Non-Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology

Cesare Gridelli, Paul Baas, Fabrice Barlesi, Fortunato Ciardiello, Lucio Crinò, Enriqueta Felip, Shirish Gadgeel, Vali Papadimitrakopoulou, Luis Paz-Ares, David Planchard, Maurice Perol, Nasser Hanna, Assunta Sgambato, Francesca Casaluce, Filippo de Marinis

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Non-small-cell lung cancer (NSCLC) patients inevitably progress to first-line therapy and further active treatments are warranted. In the past few years, new second-line therapies, beyond chemotherapy agents, have become available in clinical practice. To date, several options for the second-line treatment of non-oncogene-addicted NSCLC patients ranging from chemotherapy in combination with antivascular endothelial growth factor receptor to immunotherapeutics are available. In oncogene-driven tumors, the better knowledge of mechanisms of acquired resistance to earlier tyrosine kinase inhibitors is leading to novel active inhibitors now available/in development. The second-line algorithm treatment of NSCLC becomes very intricate and the selection of proper patients with one of the new available therapeutic options is of paramount importance to personalize and optimize the treatment. In this review we discuss the second-line treatment opportunities of addicted as well as not-addicted NSCLC.

Original languageEnglish (US)
JournalClinical Lung Cancer
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Non-Small Cell Lung Carcinoma
Thorax
Therapeutics
Vascular Endothelial Growth Factor Receptor
Combination Drug Therapy
Oncogenes
Protein-Tyrosine Kinases
Patient Selection
Drug Therapy
Neoplasms

Keywords

  • Chemotherapy
  • Combination strategies
  • Immunotherapy
  • Second-line treatment
  • Targeted therapies

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Second-Line Treatment Options in Non-Small-Cell Lung Cancer : Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. / Gridelli, Cesare; Baas, Paul; Barlesi, Fabrice; Ciardiello, Fortunato; Crinò, Lucio; Felip, Enriqueta; Gadgeel, Shirish; Papadimitrakopoulou, Vali; Paz-Ares, Luis; Planchard, David; Perol, Maurice; Hanna, Nasser; Sgambato, Assunta; Casaluce, Francesca; de Marinis, Filippo.

In: Clinical Lung Cancer, 01.01.2018.

Research output: Contribution to journalArticle

Gridelli, C, Baas, P, Barlesi, F, Ciardiello, F, Crinò, L, Felip, E, Gadgeel, S, Papadimitrakopoulou, V, Paz-Ares, L, Planchard, D, Perol, M, Hanna, N, Sgambato, A, Casaluce, F & de Marinis, F 2018, 'Second-Line Treatment Options in Non-Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology', Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2017.12.010
Gridelli, Cesare ; Baas, Paul ; Barlesi, Fabrice ; Ciardiello, Fortunato ; Crinò, Lucio ; Felip, Enriqueta ; Gadgeel, Shirish ; Papadimitrakopoulou, Vali ; Paz-Ares, Luis ; Planchard, David ; Perol, Maurice ; Hanna, Nasser ; Sgambato, Assunta ; Casaluce, Francesca ; de Marinis, Filippo. / Second-Line Treatment Options in Non-Small-Cell Lung Cancer : Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. In: Clinical Lung Cancer. 2018.
@article{b1a58639564f4ee893739f8e90c39cba,
title = "Second-Line Treatment Options in Non-Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology",
abstract = "Non-small-cell lung cancer (NSCLC) patients inevitably progress to first-line therapy and further active treatments are warranted. In the past few years, new second-line therapies, beyond chemotherapy agents, have become available in clinical practice. To date, several options for the second-line treatment of non-oncogene-addicted NSCLC patients ranging from chemotherapy in combination with antivascular endothelial growth factor receptor to immunotherapeutics are available. In oncogene-driven tumors, the better knowledge of mechanisms of acquired resistance to earlier tyrosine kinase inhibitors is leading to novel active inhibitors now available/in development. The second-line algorithm treatment of NSCLC becomes very intricate and the selection of proper patients with one of the new available therapeutic options is of paramount importance to personalize and optimize the treatment. In this review we discuss the second-line treatment opportunities of addicted as well as not-addicted NSCLC.",
keywords = "Chemotherapy, Combination strategies, Immunotherapy, Second-line treatment, Targeted therapies",
author = "Cesare Gridelli and Paul Baas and Fabrice Barlesi and Fortunato Ciardiello and Lucio Crin{\`o} and Enriqueta Felip and Shirish Gadgeel and Vali Papadimitrakopoulou and Luis Paz-Ares and David Planchard and Maurice Perol and Nasser Hanna and Assunta Sgambato and Francesca Casaluce and {de Marinis}, Filippo",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.cllc.2017.12.010",
language = "English (US)",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",

}

TY - JOUR

T1 - Second-Line Treatment Options in Non-Small-Cell Lung Cancer

T2 - Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology

AU - Gridelli, Cesare

AU - Baas, Paul

AU - Barlesi, Fabrice

AU - Ciardiello, Fortunato

AU - Crinò, Lucio

AU - Felip, Enriqueta

AU - Gadgeel, Shirish

AU - Papadimitrakopoulou, Vali

AU - Paz-Ares, Luis

AU - Planchard, David

AU - Perol, Maurice

AU - Hanna, Nasser

AU - Sgambato, Assunta

AU - Casaluce, Francesca

AU - de Marinis, Filippo

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Non-small-cell lung cancer (NSCLC) patients inevitably progress to first-line therapy and further active treatments are warranted. In the past few years, new second-line therapies, beyond chemotherapy agents, have become available in clinical practice. To date, several options for the second-line treatment of non-oncogene-addicted NSCLC patients ranging from chemotherapy in combination with antivascular endothelial growth factor receptor to immunotherapeutics are available. In oncogene-driven tumors, the better knowledge of mechanisms of acquired resistance to earlier tyrosine kinase inhibitors is leading to novel active inhibitors now available/in development. The second-line algorithm treatment of NSCLC becomes very intricate and the selection of proper patients with one of the new available therapeutic options is of paramount importance to personalize and optimize the treatment. In this review we discuss the second-line treatment opportunities of addicted as well as not-addicted NSCLC.

AB - Non-small-cell lung cancer (NSCLC) patients inevitably progress to first-line therapy and further active treatments are warranted. In the past few years, new second-line therapies, beyond chemotherapy agents, have become available in clinical practice. To date, several options for the second-line treatment of non-oncogene-addicted NSCLC patients ranging from chemotherapy in combination with antivascular endothelial growth factor receptor to immunotherapeutics are available. In oncogene-driven tumors, the better knowledge of mechanisms of acquired resistance to earlier tyrosine kinase inhibitors is leading to novel active inhibitors now available/in development. The second-line algorithm treatment of NSCLC becomes very intricate and the selection of proper patients with one of the new available therapeutic options is of paramount importance to personalize and optimize the treatment. In this review we discuss the second-line treatment opportunities of addicted as well as not-addicted NSCLC.

KW - Chemotherapy

KW - Combination strategies

KW - Immunotherapy

KW - Second-line treatment

KW - Targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=85041237037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041237037&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2017.12.010

DO - 10.1016/j.cllc.2017.12.010

M3 - Article

C2 - 29396237

AN - SCOPUS:85041237037

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

ER -